Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cisplatin + osimertinib + pemetrexed
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of two platinum-based agents (carboplatin and cisplatin), a targeted therapy (osimertinib), and an antifolate chemotherapy drug (pemetrexed). The platinum compounds work by forming DNA cross-links that interfere with cell division, while osimertinib targets EGFR mutations, and pemetrexed inhibits enzymes necessary for purine and pyrimidine synthesis. This combination likely aims to leverage the different toxicity profiles and mechanisms of action of these drugs to enhance efficacy in treating advanced cancers, particularly non-small cell lung cancer.
- Other names
- osimertinibAZD9291AZD-9291AZD 9291pemetrexed disodiumcarboplatincis-diamminedichloroplatinum(II)
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on carboplatin + cisplatin + osimertinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cisplatin + osimertinib + pemetrexed.